3 recruiting, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 3 Phase 3, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Mitomycin C (MMC): new trials by email Literature Review of Mitomycin C (MMC) trials Research Report on Mitomycin C (MMC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) - Peritoneal Carcinomatosis | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2026-08-05 | 2026-09-16 |
| Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients Mitomycin C (MMC), Normal Saline (Placebo) - Non-Muscle-Invasive Bladder Cancer (NMIBC) | Phase 3 | Recruiting | Shaogang Wang | 180 | 2025-02-17 | 2025-02-19 |
| Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin, Mitomycin C (MMC) - Non-Muscle-Invasive Bladder Cancer (NMIBC) | Phase 2 | Recruiting | Shanxi Province Cancer Hospital | 30 | 2024-04-01 | 2026-06-12 |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes) - Urinary Bladder Neoplasms | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 520 | 2020-05-19 | 2026-05-01 |
| Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients Mitomycin C (MMC), Bacillus Calmette-Guerin (BCG) - Bladder Cancer | Phase 3 | Terminated | Memorial Sloan Kettering Cancer Center | 50 | 2009-09-01 | 2015-11-20 |
| Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma Ahmed Glaucoma Valve (AGV), Mitomycin C (MMC), amniotic membrane coverage - Refractory Glaucoma | Phase 1 | Unknown | Shahid Beheshti University of Medical Sciences | 2009-05-06 |
Non-Muscle Invasive Bladder Neoplasms (3) · Urinary Bladder Neoplasms (3) · Appendiceal Neoplasms (1) · Carcinoma in Situ (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Glaucoma (1) · Peritoneal Diseases (1) · Peritoneal Neoplasms (1)
First Affiliated Hospital of Wenzhou Medical University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Shahid Beheshti University of Medical Sciences (1) · Shanxi Province Cancer Hospital (1) · Shaogang Wang (1)
China (3) · United States (3) · Australia (1) · Chile (1) · Czechia (1) · Denmark (1) · Estonia (1) · France (1) · Guatemala (1) · Hungary (1) · Iran (1) · Israel (1) · Italy (1) · Japan (1) · Latvia (1)
Guido Dalbagni, MD (1) · Sean Dineen, MD (1)
PMID 19171491, PMID 23510863, PMID 34051177, PMID 37596191, PMID 38265030, PMID 38740030
2019 (1), 2023 (1)